Portfolio company
Adalid Science
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Adalid Sciences develops lipid nanoparticle delivery systems for nucleic acid therapeutics, serving pharmaceutical companies, biotechnology start-ups, and contract development and manufacturing organisations.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Etherna
This company develops mRNA and lipid nanoparticle technologies for pharmaceutical and biotechnology partners to create nucleic acid-based medicines and vaccines.
RNAnalytics
This company develops modular analysis toolkits and software for lipid nanoparticle characterisation to support biotech and pharmaceutical firms developing RNA-based therapies.
Axelyf
The company develops lipid nanoparticle delivery systems and RNA therapeutics for pharmaceutical developers and patients with oncology or autoimmune diseases.
Argonaute RNA
This biotechnology firm develops bispecific siRNA therapeutics for cardiometabolic diseases, serving pharmaceutical partners and research institutions engaged in advanced therapeutic research.
Nuntius Therapeutics
This company develops mRNA and gene-editing therapies using a programmable nanocarrier delivery platform for pharmaceutical companies and research institutions.
Breeze
This company develops polymer nanoparticles to enable the non-viral delivery of RNA therapeutics to extrahepatic tissues for biotechnology and pharmaceutical organisations.
Hone Bio
This company develops lipid nanoparticle targeting technology for pharmaceutical and biotechnology firms to enable precise drug delivery beyond the liver.
Altamira Therapeutics
This company develops peptide-based nanoparticle technologies for RNA delivery to pharmaceutical industry partners developing treatments for cancer and inflammatory diseases.
